{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:13:28Z","timestamp":1785683608485,"version":"3.56.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>\n                    Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary cutaneous follicle center lymphoma (PCFCL) are cutaneous B-cell lymphomas (CBCL) with different clinical characteristics and behavior. PCDLBCL-LT is the most aggressive CBCL with a relatively poor prognosis. In nodal diffuse large B-cell lymphoma (DLBCL), rearrangements of the\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    gene, especially in combination with a second hit in\n                    <jats:italic toggle=\"yes\">BCL2<\/jats:italic>\n                    and\/or\n                    <jats:italic toggle=\"yes\">BCL6<\/jats:italic>\n                    , and double protein expression of MYC and BCL2 (DE) are adverse prognostic factors. As the clinical significance of these factors in CBCL is largely unknown, we studied the frequency and prognostic value of\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    rearrangements and DE in a cohort of 44 patients with PCDLBCL-LT and 17 patients with PCFCL. Compared with nodal DLBCL (9% to 14%), the PCDLBCL-LT patients had a high incidence of\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    rearrangements (32%), but only 2 patients (4%) had a second hit, both with\n                    <jats:italic toggle=\"yes\">BCL6<\/jats:italic>\n                    . PCDLBCL-LT patients with a\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    rearrangement showed an inferior disease-specific survival (Log-rank,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.036) and disease-free survival (Log-rank,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.028), but no significant adverse effect on overall survival (Log-rank,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.157) at 5 years compared with patients without a\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    rearrangement. DE, present in 65% of the PCDLBCL-LT patients, was not associated with reduced survival. In the PCFCL group,\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    rearrangements and DE were not detected. In conclusion, this study identifies a high incidence of\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    rearrangements in PCDLBCL-LT compared to nodal DLBCL and further shows that a\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    rearrangement is an inferior prognostic marker in these patients. Therefore, our data suggest that it is useful to perform\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    -FISH in all newly diagnosed PCDLBCL-LT patients.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000001132","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T15:41:41Z","timestamp":1534261301000},"page":"1488-1494","source":"Crossref","is-referenced-by-count":53,"title":["High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type"],"prefix":"10.1097","volume":"42","author":[{"given":"Anne M.R.","family":"Schrader","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty M.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna K.","family":"Kleiverda","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost S.P.","family":"Vermaat","sequence":"additional","affiliation":[{"name":"Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/jid.2008.357","article-title":"Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"129","author":"Senff","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","article-title":"Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study","volume":"19","author":"Grange","year":"2001","journal-title":"J Clin Oncol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","article-title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","volume":"27","author":"Tzankov","year":"2014","journal-title":"Mod Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of \u201cdouble hit\u201d diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cjp2.10","article-title":"The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit","volume":"1","author":"Clipson","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","article-title":"High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma","volume":"31","author":"Rosenthal","year":"2017","journal-title":"Blood Rev"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J Clin Oncol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/jid.2013.265","article-title":"Nuclear factor-kappaB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type","volume":"134","author":"Koens","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Pham-Ledard","year":"2014","journal-title":"Mod Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg-type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.0022-202X.2004.22720.x","article-title":"Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas","volume":"123","author":"Hallermann","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.pas.0000155163.40668.e7","article-title":"Genetic aberrations in primary cutaneous large B-cell lymphoma: a fluorescence in situ hybridization study of 25 cases","volume":"29","author":"Wiesner","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41379-018-0041-7","article-title":"Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas","volume":"31","author":"Menguy","year":"2018","journal-title":"Mod Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pone.0114398","article-title":"MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system","volume":"9","author":"Gill","year":"2014","journal-title":"Plos One"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-013-1169-7","article-title":"Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2(low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas","volume":"126","author":"Brunn","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1200\/JCO.2008.16.1455","article-title":"Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course","volume":"26","author":"Cady","year":"2008","journal-title":"J Clin Oncol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.18632\/oncotarget.6262","article-title":"Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cam4.865","article-title":"Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: comparison with current classification and definition of prognostic markers","volume":"5","author":"Lucioni","year":"2016","journal-title":"Cancer Med"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/apm.12390","article-title":"MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system","volume":"123","author":"Tapia","year":"2015","journal-title":"APMIS"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12885-016-2397-8","article-title":"MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnen\/nlx083","article-title":"MYC\/BCL2 co-expression is a stronger prognostic factor compared with the cell-of-origin classification in primary CNS DLBCL","volume":"76","author":"Shi","year":"2017","journal-title":"J Neuropath Exp Neur"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","article-title":"High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-015-0374-0","article-title":"Aggressive B cell lymphoma: optimal therapy for MYC-positive, double-hit, and triple-hit DLBCL","volume":"16","author":"Dunleavy","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","article-title":"The MYC oncogene is a global regulator of the immune response","volume":"131","author":"Casey","year":"2018","journal-title":"Blood"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201811000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T18:45:51Z","timestamp":1695408351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201811000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001132","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733826394.793559646","asserted-by":"object"}]},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}